(S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride
• 英文别名: (S)-1-(5-bromo-4-methylpyridin-2-yl)ethylamine hydrochloride；(S)-1-(5-Bromo-4-methylpyridin-2-yl)ethanamine hydrochloride；(1S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine;hydrochloride
• 化学式: C₈H₁₁BrN₂*ClH
• 分子量: 251.554
• InChiKey: XNXZPUVFWDMCIG-RGMNGODLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.59
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  38.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one 、 (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride 在 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成 (4R)-3-[2-[[(1S)-1-(5-bromo-4-methylpyridin-2-yl)ethyl]amino]pyrimidin-4-yl]-4-[(1S)-1-fluoroethyl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  [EN] THERAPEUTIC CONJUGATES
  [FR] CONJUGUÉS THÉRAPEUTIQUES

  摘要：

  本公开涉及与生物靶点共价结合的治疗性结合物。本文还提供了将该组合物用于治疗需要的受试者的方法。

  公开号：

  WO2022056453A1

文献信息

• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：NOVARTIS AG

  公开号：US20150152093A1

  公开（公告）日：2015-06-04

  The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2a , R 2b and R 3 -R 7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及一种公式(I)或其药学上可接受的盐，其中R1、R2a、R2b和R3-R7如下。该发明还涉及含有公式(I)化合物的组合物，并且涉及使用这些化合物来抑制具有新型活性的突变IDH蛋白质。该发明进一步涉及使用公式(I)化合物来治疗与这种突变IDH蛋白质相关的疾病或障碍，包括但不限于细胞增殖障碍，如癌症。
• 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
  申请人：Caferro Thomas Raymond

  公开号：US09434719B2

  公开（公告）日：2016-09-06

  The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  本发明涉及一种公式(I)或其药学上可接受的盐，其中R1，R2a，R2b和R3-R7如下。本发明还涉及含有公式(I)化合物的组合物，并且涉及使用这种化合物来抑制具有新异构酶活性的突变IDH蛋白质。本发明进一步涉及使用公式(I)化合物来治疗与这种突变IDH蛋白质相关的疾病或障碍，包括但不限于细胞增殖障碍，如癌症。
• US9434719B2
  申请人：——

  公开号：US9434719B2

  公开（公告）日：2016-09-06
• US9688672B2
  申请人：——

  公开号：US9688672B2

  公开（公告）日：2017-06-27